NCT05487417 (MIST-A) is a Phase 4 clinical trial of Minocycline in Ischemic Stroke, Acute, sponsored by Xijing Hospital.

Who is sponsoring NCT05487417?

NCT05487417 is sponsored by Xijing Hospital.

What drugs are being tested in NCT05487417?

Interventions in NCT05487417: Minocycline.

What condition does NCT05487417 study?

NCT05487417 studies Ischemic Stroke, Acute.

Is NCT05487417 still recruiting?

NCT05487417 is currently recruiting now. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT05487417: MIST-A

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Recruiting now Phase 4 Last updated 24 July 2025

What this trial tests

Phase 4 trial testing Minocycline in Ischemic Stroke, Acute in 180 participants. Currently enrolling.

Timeline

1 November 2022

Primary endpoint
10 June 2025

10 September 2025

Quick facts

Lead sponsor	Xijing Hospital
Phase	Phase 4
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	180
Start date	1 November 2022
Primary completion	10 June 2025
Estimated completion	10 September 2025
Sites	1 location across China

Drugs / interventions tested

Minocycline (MINOCYCLINE) — full drug profile →

Conditions studied

Ischemic Stroke, Acute — all drugs for Ischemic Stroke, Acute →

Sponsor

Xijing Hospital

Who can join

Adults 18 to 85, any sex, with Ischemic Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of minocycline on patients with acute anterior circulation ischaemic stroke undergoing intravenous thrombectomy (MIST-A): the study protocol for a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
Zhang X, Zhao J, Sun Z, Wei D, et al · · 2024 · cited 3× · PMID 39806586 · DOI 10.1136/bmjopen-2024-093443
Rationale and Study Design to Assess the Efficacy and Safety of Minocycline in Patients with Moderate to Severe Acute Ischaemic Stroke (EMPHASIS).
Lu Y, Guan L, Zhang M, Yang Q, et al · · 2025 · cited 1× · PMID 40147820 · DOI 10.1136/svn-2024-003577

Verify or expand the search:

Other trials of Minocycline

Trials testing the same drug.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting

Other recruiting trials for Ischemic Stroke, Acute

Currently open trials in the same condition.

NCT06639360 — Effects of Transcranial Magnetic Stimulation After Endovascular Treatment for Acute Ischemic Stroke · NA · recruiting
NCT07043686 — Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study · NA · recruiting
NCT06920303 — Accuracy of Transcranial Colour Coded Duplex in Comparing With CT Angiography · recruiting
NCT06712004 — A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke · Phase 2 · recruiting
NCT06726941 — Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia · NA · recruiting

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05487417 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05487417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing